Vincerx Pharma is a clinical-stage biopharmaceutical company developing cancer therapies, with no approved products and no product revenue. Vincerx's pipeline is built around its proprietary VersAptx bioconjugation platform, which combines targeting molecules, linkers, and cancer-killing payloads into antibody-drug conjugates (ADCs) and small molecule drug conjugates (SMDCs) designed to selectively destroy tumor cells. All pipeline assets are licensed exclusively from Bayer. The lead asset, VIP943, is an ADC targeting CD123 in blood cancers including AML and B-ALL, currently in Phase 1 trials with early signs of antitumor activity. VIP924 is a preclinical ADC targeting CXCR5 in B-cell lymphomas, and VIP236 is an SMDC targeting solid tumors that completed Phase 1 in late 2024. Vincerx also has enitociclib, a CDK9 inhibitor in early trials for DLBCL and T-cell lymphoma. The intended business model involves out-licensing or partnering pipeline assets to larger pharma companies in exchange for upfront payments, milestones, and royalties, rather than building its own commercial infrastructure. However, Vincerx is effectively in strategic wind-down mode — the company had roughly $4.7M in cash as of March 2025, enough only into Q3 2025, and has raised going concern doubts. Vincerx is pursuing a proposed reverse merger with QumulusAI, a cloud computing company, under which Vincerx shareholders would retain only 5% of the combined entity.